Genomic DNA at user-defined loci (gDNA)

Genomic DNA at user-defined loci refers to specific sequences within the cellular genome that are intentionally targeted for modification by therapeutic agents, most notably programmable nucleases like CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), and Transcription Activator-Like Effector Nucleases (TALENs) (Jinek et al., 2012, Science). As the fundamental blueprint of life, genomic DNA stores the instructions for protein synthesis and cellular function; however, mutations or dysregulation at specific loci can lead to a wide array of genetic disorders and cancers. By targeting these precise locations, modern gene-editing therapies aim to correct pathogenic mutations, disrupt deleterious genes, or insert therapeutic sequences to restore normal physiological function (Doudna & Charpentier, 2014, Nature). The interaction typically involves a guide molecule or DNA-binding domain that directs an effector enzyme to the target site, where it induces a double-strand break or chemical modification. For instance, exagamglogene autotemcel targets the BCL11A enhancer to treat sickle cell disease (FDA, 2023). While this approach offers curative potential for previously untreatable conditions, it also presents significant challenges, including the risk of off-target effects where unintended parts of the genome are altered, potentially leading to oncogenesis or other cellular dysfunctions (Fu et al., 2013, Nature Biotechnology). Consequently, the development of drugs for this target requires rigorous validation of specificity and long-term monitoring of genomic integrity.

Other names

Target DNA sequenceChromosomal DNAGenomic locusSite-specific DNA

Site-specific modification of genomic sequences via programmable nucleases (e.g., Cas9, ZFNs) or chemical modifiers (e.g., base editors) to achieve gene disruption, correction, or insertion (Jinek et al., 2012, Science).